Puma Biotechnology (PBYI) Competitors $3.39 +0.11 (+3.35%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$3.39 0.00 (0.00%) As of 05/16/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PBYI vs. BCYC, ANAB, COGT, VECT, SION, KROS, IMTX, TYRA, VALN, and MRVIShould you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include Bicycle Therapeutics (BCYC), AnaptysBio (ANAB), Cogent Biosciences (COGT), VectivBio (VECT), Sionna Therapeutics (SION), Keros Therapeutics (KROS), Immatics (IMTX), Tyra Biosciences (TYRA), Valneva (VALN), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry. Puma Biotechnology vs. Bicycle Therapeutics AnaptysBio Cogent Biosciences VectivBio Sionna Therapeutics Keros Therapeutics Immatics Tyra Biosciences Valneva Maravai LifeSciences Bicycle Therapeutics (NASDAQ:BCYC) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends. Does the MarketBeat Community favor BCYC or PBYI? Puma Biotechnology received 412 more outperform votes than Bicycle Therapeutics when rated by MarketBeat users. However, 70.53% of users gave Bicycle Therapeutics an outperform vote while only 67.39% of users gave Puma Biotechnology an outperform vote. CompanyUnderperformOutperformBicycle TherapeuticsOutperform Votes14670.53% Underperform Votes6129.47% Puma BiotechnologyOutperform Votes55867.39% Underperform Votes27032.61% Which has stronger earnings and valuation, BCYC or PBYI? Puma Biotechnology has higher revenue and earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicycle Therapeutics$25.72M21.81-$180.66M-$3.14-2.58Puma Biotechnology$232.71M0.72$21.59M$0.774.40 Do insiders and institutionals hold more shares of BCYC or PBYI? 86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 22.9% of Bicycle Therapeutics shares are held by company insiders. Comparatively, 23.7% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, BCYC or PBYI? Bicycle Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Do analysts rate BCYC or PBYI? Bicycle Therapeutics currently has a consensus price target of $25.00, suggesting a potential upside of 208.64%. Puma Biotechnology has a consensus price target of $7.00, suggesting a potential upside of 106.49%. Given Bicycle Therapeutics' higher probable upside, equities analysts clearly believe Bicycle Therapeutics is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicycle Therapeutics 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.70Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BCYC or PBYI more profitable? Puma Biotechnology has a net margin of 9.56% compared to Bicycle Therapeutics' net margin of -450.64%. Puma Biotechnology's return on equity of 41.60% beat Bicycle Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bicycle Therapeutics-450.64% -27.35% -20.81% Puma Biotechnology 9.56%41.60%10.71% Does the media favor BCYC or PBYI? In the previous week, Bicycle Therapeutics had 6 more articles in the media than Puma Biotechnology. MarketBeat recorded 10 mentions for Bicycle Therapeutics and 4 mentions for Puma Biotechnology. Bicycle Therapeutics' average media sentiment score of 0.54 beat Puma Biotechnology's score of 0.30 indicating that Bicycle Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Puma Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryPuma Biotechnology beats Bicycle Therapeutics on 10 of the 18 factors compared between the two stocks. Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBYI vs. The Competition Export to ExcelMetricPuma BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$168.25M$6.44B$5.36B$8.52BDividend YieldN/A2.67%4.95%4.12%P/E Ratio7.069.1626.9120.00Price / Sales0.72247.33389.58119.42Price / Cash4.1965.8538.2534.62Price / Book3.036.456.764.60Net Income$21.59M$143.73M$3.23B$248.70M7 Day Performance16.49%4.47%4.87%5.15%1 Month Performance18.53%7.93%9.91%13.68%1 Year Performance-17.22%-5.48%14.89%6.77% Puma Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBYIPuma Biotechnology3.73 of 5 stars$3.39+3.4%$7.00+106.5%-23.1%$168.25M$232.71M7.06200BCYCBicycle Therapeutics3.8467 of 5 stars$8.60+3.1%$25.00+190.7%-63.5%$595.14M$25.72M-2.61240Gap DownANABAnaptysBio3.3351 of 5 stars$20.03+2.2%$35.88+79.1%-20.6%$588.48M$111.87M-3.29100Positive NewsCOGTCogent Biosciences2.4226 of 5 stars$5.13+6.7%$14.29+178.5%-34.7%$584.08MN/A-2.0780Positive NewsVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeSIONSionna TherapeuticsN/A$12.90+4.7%$38.50+198.4%N/A$569.20MN/A0.0035News CoverageEarnings ReportKROSKeros Therapeutics3.0509 of 5 stars$13.74+0.7%$37.00+169.3%-73.9%$558.05M$214.71M-2.64100IMTXImmatics2.8664 of 5 stars$4.56+7.5%$16.67+265.5%-56.2%$554.27M$155.84M-6.91260News CoveragePositive NewsEarnings ReportAnalyst RevisionGap UpTYRATyra Biosciences1.7279 of 5 stars$10.26+1.7%$30.83+200.5%-47.7%$544.70MN/A-6.3720News CoveragePositive NewsVALNValneva2.3634 of 5 stars$6.45-0.3%$15.50+140.3%-28.3%$539.45M$169.58M-49.62700MRVIMaravai LifeSciences4.1319 of 5 stars$2.12+7.1%$6.34+199.2%-81.1%$539.19M$259.19M-1.29610Earnings ReportAnalyst ForecastOptions VolumeGap Up Related Companies and Tools Related Companies Bicycle Therapeutics Competitors AnaptysBio Competitors Cogent Biosciences Competitors VectivBio Competitors Sionna Therapeutics Competitors Keros Therapeutics Competitors Immatics Competitors Tyra Biosciences Competitors Valneva Competitors Maravai LifeSciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBYI) was last updated on 5/17/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PBYI Stock Free PBYI Stock Alerts